Mounjaro is Eli Lilly’s GLP-1 drug for obesity and type 2 diabetes, facing FDA safety labeling on NAION risk amid rising demand and ongoing litigation and market competition.
The FDA has required warning labels on GLP-1 drugs used for obesity and diabetes after reviewing data that link a rare eye condition, NAION, to these medications. The warning covers a dozen drugs, including Ozempic, Wegovy, Mounjaro and Zepbound. Trials and real-world data show NAION occurrences are rare but higher than in non-GLP-1 therapies.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
New episodes and updates across Northstar Politics and Manifesto examine accountability in politics, the role of wealth taxes, religion in leftist discourse, and a mass-shooter manifesto turned documentary project. Independent pieces highlight how platforms shape political imagination and how a true-crime format reframes public understanding of violence.
A BBC Business report notes rising use of weight-loss drugs in 2024-25, with a focus on male users and safety concerns, while other outlets explore personal journeys with GLP-1 medications and gut health trends.
New observational data suggests Shingrix vaccination in older adults is associated with lower cardiovascular risk and reduced dementia incidence over multi-year follow-ups. Studies compare Shingrix to Zostavax and find reductions in heart disease, stroke, and dementia, with stronger signals in men for heart outcomes.
A study from Anglia Ruskin University finds traditional dieting is less effective for men, who view dieting as restrictive and feminine. Partners often support men, while male-focused programmes that emphasize quick wins, social competition and strength may boost engagement. Researchers advocate practical, non-dieting strategies and sport-related challenges.
GLP-1 medications are being increasingly prescribed off-label to children aged 8–11 in the US, despite no FDA approval for under-12s. A NYU Langone study shows a dramatic rise in June 2026, while experts warn about long-term effects and the broader obesity crisis.
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
Companies are reviewing coverage for GLP-1 weight-loss drugs as costs rise. Some have already trimmed benefits, while others cite long-term employee health benefits as a reason to maintain or adjust coverage. The trend could raise healthcare costs for employers and influence benefits strategies.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
Lawsuits allege GLP-1 diabetes drugs may cause nonarteritic anterior ischemic optic neuropathy (NAION), an eye condition that can cause permanent vision loss. Novo Nordisk and Eli Lilly dispute the claims as regulators review data; meanwhile trials and studies show mixed signals about risk.
Walmart has expanded benefits for associates, adding 12 weeks of neonatal ICU leave and enabling second opinions for rare conditions. It also joins Novo and Lilly drug coverage for Type 2 diabetics at no cost, while premium increases are minimized. The moves come ahead of open enrollment and build on years of compensation improvements.
FDA warns that GLP-1 receptor agonists may carry a rare risk of nonarteritic anterior ischemic optic neuropathy, prompting safety labels and clinical monitoring. New labels affect Ozempic, Wegovy, Zepbound and Mounjaro as agencies push patients and providers to report vision changes promptly. Regulators say the risk is rare but serious, with guidance to discontinue therapy if NAION develops.